Hyperbaric Oxygen Therapy Chronic Fatigue Syndrome: What Research Shows

Chronic fatigue syndrome, also known as myalgic encephalomyelitis (ME/CFS), leaves many people searching beyond standard care for options that might ease their symptoms. Hyperbaric oxygen therapy chronic fatigue syndrome research has drawn growing interest as one such option, though the science is still in its early stages. A small number of studies have looked at whether breathing pressurized oxygen can help with ME/CFS symptoms, and the results so far are limited and mixed. This article walks through what the current, still-developing evidence actually shows, how HBOT works, what safety data exists, and what questions remain unanswered.

What Is Chronic Fatigue Syndrome (ME/CFS)?

ME/CFS is a complex, long-term illness marked by profound fatigue that does not improve with rest, along with post-exertional malaise (a worsening of symptoms after physical or mental activity), unrefreshing sleep, and cognitive difficulties often described as "brain fog" (Institute of Medicine, Beyond ME/CFS: Redefining an Illness, 2015). The underlying biology is not fully understood, but researchers have proposed that mitochondrial dysfunction and oxidative or nitrosative stress - essentially, disruptions in how cells produce and manage energy - may contribute to symptoms in at least some patients (Morris & Maes, Metabolic Brain Disease, 2014). This mechanistic hypothesis is part of why some researchers have proposed oxygen-based therapies as a potential area worth studying in ME/CFS, though a proposed mechanism does not, on its own, establish that a treatment works.

What Is Hyperbaric Oxygen Therapy?

Hyperbaric oxygen therapy involves breathing 100% oxygen inside a pressurized chamber, which increases the amount of oxygen dissolved directly in the blood plasma well beyond what normal breathing provides. This elevated oxygen delivery is thought to support cellular repair processes, influence cell-signaling pathways, and reduce certain inflammatory responses (Thom, Plastic and Reconstructive Surgery, 2011). These are general physiological effects observed with HBOT across a range of conditions, not findings specific to ME/CFS. At a clinical setting like Humanaut Health, sessions are administered by trained clinical staff under monitored conditions rather than as a self-directed treatment.

What Does the Research Show?

Early and Mixed Findings

Research directly evaluating HBOT for chronic fatigue syndrome is limited to a small number of studies. The earliest, a 2003 controlled trial in CFS patients, found no significant overall improvement across most quality-of-life measures, with only a possible trend toward reduced bodily pain in one subgroup (Van Hoof et al., Journal of Chronic Fatigue Syndrome, 2003). A decade later, a small uncontrolled trial of 16 patients who completed 15 HBOT sessions over three weeks reported significant improvements on three fatigue-severity measures (Akarsu et al., Undersea & Hyperbaric Medicine, 2013). However, this study had no comparison group and did not track patients after treatment ended, so it cannot show whether any benefit lasted.

A Closer Look at Recent Research

The most detailed ME/CFS-specific study to date is a 2026 prospective cohort study of 30 patients who completed 40 HBOT sessions over 8 to 16 weeks. It found significant improvements in physical functioning, pain, fatigue, exercise capacity, and cognitive processing speed, along with changes in brain connectivity patterns on imaging (Kim et al., Journal of Translational Medicine, 2026). This study is more methodologically detailed than earlier ones, but it still lacked a placebo or sham-treatment control group. The study authors themselves note that the improvements cannot be unequivocally attributed to HBOT, since natural symptom fluctuation or a placebo response cannot be ruled out without a sham comparison.

Evidence From Related Conditions

Because direct ME/CFS evidence is so limited, it's worth noting research in related conditions that share fatigue and cognitive symptoms with ME/CFS, while being clear these are different diagnoses. A sham-controlled randomized trial in post-COVID condition - a distinct diagnosis, not ME/CFS - found significant improvements in cognitive function, fatigue, sleep, and pain interference with HBOT compared with a sham treatment (Zilberman-Itskovich et al., Scientific Reports, 2022). Similarly, randomized trials in fibromyalgia, a condition that frequently overlaps with ME/CFS, have found HBOT associated with reduced pain and improved quality of life, though one trial noted that benefits partially regressed after treatment stopped (Efrati et al., PLOS ONE, 2015; da Mota Neto et al., BMJ Open, 2026). These related-condition trials used stronger designs than the ME/CFS-specific studies, but they cannot be treated as direct evidence for ME/CFS itself.

Taken together, no sham-controlled randomized trial testing HBOT specifically in ME/CFS has been published as of this writing. One such trial is currently recruiting participants, and its results, once available, should meaningfully clarify the picture.

What Do Experts and Guidelines Say?

Hyperbaric oxygen therapy is not an FDA-approved or cleared treatment for chronic fatigue syndrome or ME/CFS. No major medical society currently recommends HBOT as standard care for this condition, and available clinical guidance continues to describe the research as preliminary. Anyone considering HBOT for chronic fatigue syndrome should treat it as an area of ongoing investigation rather than an established therapy, and should discuss it with a qualified healthcare professional familiar with their full medical history.

How Does HBOT Compare to Other Options?

HBOT is one of several oxygenation-focused approaches that have been explored for fatigue-related symptoms. Humanaut Health also offers EBO2 therapy, an extracorporeal blood oxygenation and ozonation approach that addresses chronic fatigue through a different mechanism, and HBOT is sometimes used alongside stem cell therapy as part of a broader recovery-support plan. None of these approaches has been shown to be superior to the others for ME/CFS specifically, and the evidence supporting each varies. Choosing among them is an individualized decision best made with a clinician who can review your health history and goals.

Is Hyperbaric Oxygen Therapy Safe?

In a large retrospective analysis of more than 2,300 patients receiving HBOT across various conditions, the overall adverse event rate was approximately 0.72% per session, and the most common issue was mild middle-ear barotrauma, or pressure-related ear discomfort (Hadanny et al., Undersea & Hyperbaric Medicine, 2016). Other effects, such as sinus discomfort, temporary vision changes, or lightheadedness, were reported less frequently. Certain conditions, such as untreated pneumothorax or specific ear or lung issues, generally require careful screening before HBOT. This is general safety information, not individualized medical advice - a clinical evaluation is the appropriate way to determine whether HBOT is suitable for a particular person.

What Can You Expect?

Because the ME/CFS-specific evidence base is still so limited, it is not possible to predict with confidence how any individual might respond to HBOT. Study protocols have varied widely, from 15 sessions over three weeks to 40 sessions over several months, and none have established a standard protocol for ME/CFS. In related-condition research, some reported benefits diminished after treatment ended, suggesting that any improvements may not be permanent without ongoing care. Individual responses vary considerably, and no outcome can be guaranteed.

Frequently Asked Questions

Is hyperbaric oxygen therapy chronic fatigue syndrome treatment FDA-approved?

No. HBOT is not an FDA-approved or cleared indication for ME/CFS. Research remains preliminary, and any decision to try it should involve a qualified healthcare professional.

What does the research say about hyperbaric oxygen therapy for chronic fatigue?

Findings are mixed and based on small studies. An early controlled trial found little overall benefit, while a small uncontrolled trial and a more recent cohort study reported improvements in fatigue and physical functioning - but none of these studies used a placebo or sham control.

Has chronic fatigue syndrome hyperbaric oxygen therapy been tested in a large clinical trial?

Not yet. No sham-controlled randomized trial specifically testing HBOT in ME/CFS has been published. One is currently recruiting participants, and its results are not yet available.

Can hyperbaric oxygen therapy cure chronic fatigue syndrome?

No treatment, including HBOT, has been shown to cure ME/CFS. Early research suggests HBOT may help ease some symptoms in certain patients, but this has not been confirmed in large controlled studies.

Is HBOT safe for people with chronic fatigue syndrome?

In general HBOT populations, side effects are uncommon and usually mild, such as ear pressure or discomfort. Individual suitability depends on personal health history, so a clinical evaluation is recommended before starting.

How many HBOT sessions have researchers studied for ME/CFS?

Study protocols have varied, from 15 sessions over three weeks in one small trial to 40 sessions over 8 to 16 weeks in the most recent cohort study. There is no established standard protocol specific to ME/CFS.

How does HBOT compare to other therapies for chronic fatigue?

Some clinics, including Humanaut Health, offer other oxygenation-based approaches like EBO2 therapy alongside HBOT, and HBOT is sometimes used together with therapies such as stem cell therapy. No approach has been proven superior for ME/CFS specifically.

How soon might someone notice a difference with HBOT?

In the studies available, changes were assessed after a full course of sessions spanning several weeks, not after a single visit. Individual responses vary widely, and any reported improvements may not persist once treatment stops.

Key Takeaways

• Evidence for hyperbaric oxygen therapy chronic fatigue syndrome treatment is early and limited, drawn from only a handful of small studies.
• The earliest controlled trial found little benefit; more recent uncontrolled studies reported improvements, but none used a placebo or sham control.
• No sham-controlled randomized trial in ME/CFS has been published yet; one is currently recruiting.
• HBOT is not an FDA-approved or cleared treatment for ME/CFS, and no major medical society currently recommends it as standard care.
• General HBOT safety data suggest side effects are uncommon and usually mild, but individualized medical guidance is essential before considering treatment.

If you're exploring options for managing chronic fatigue symptoms, Humanaut Health's hyperbaric oxygen therapy program offers a personalized clinical evaluation to help determine whether it may be appropriate for you.